The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with advanced renal cell carcinoma (aRCC). Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor monoclonal antibody, was approved as monotherapy in 2015 for aRCC after treatment with a VEGF-targeting agent. In April 2018, the combination of nivolumab and ipilimumab, a CTLA-4 inhibitor, was approved for intermediate- and poor-risk, previously untreated patients with aRCC. Then, in 2019, combinations therapies consisting of pembrolizumab (anti-PD-1) or avelumab (anti-PD-ligand (L) 1) with axitinib (a VEGF receptor tyrosine kinase inhibitor) were also approved to treat aRCC and are likely to produce dramatic shifts in the therapeutic landscape. To address the rapid advances in immunotherapy options for patients with aRCC, the Society for Immunotherapy of Cancer (SITC) reconvened its Cancer Immunotherapy Guidelines (CIG) Renal Cell Carcinoma Subcommittee and tasked it with generating updated consensus recommendations for the treatment of patients with this disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Journal for immunotherapy of cancer - 7(2019), 1 vom: 20. Dez., Seite 354 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rini, Brian I [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 21.07.2020 Date Revised 27.04.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s40425-019-0813-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM304575054 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM304575054 | ||
| 003 | DE-627 | ||
| 005 | 20231225115259.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s40425-019-0813-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1015.xml |
| 035 | |a (DE-627)NLM304575054 | ||
| 035 | |a (NLM)31856918 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rini, Brian I |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC) |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.07.2020 | ||
| 500 | |a Date Revised 27.04.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with advanced renal cell carcinoma (aRCC). Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor monoclonal antibody, was approved as monotherapy in 2015 for aRCC after treatment with a VEGF-targeting agent. In April 2018, the combination of nivolumab and ipilimumab, a CTLA-4 inhibitor, was approved for intermediate- and poor-risk, previously untreated patients with aRCC. Then, in 2019, combinations therapies consisting of pembrolizumab (anti-PD-1) or avelumab (anti-PD-ligand (L) 1) with axitinib (a VEGF receptor tyrosine kinase inhibitor) were also approved to treat aRCC and are likely to produce dramatic shifts in the therapeutic landscape. To address the rapid advances in immunotherapy options for patients with aRCC, the Society for Immunotherapy of Cancer (SITC) reconvened its Cancer Immunotherapy Guidelines (CIG) Renal Cell Carcinoma Subcommittee and tasked it with generating updated consensus recommendations for the treatment of patients with this disease | ||
| 650 | 4 | |a Consensus Development Conference | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Guidelines | |
| 650 | 4 | |a Immune checkpoint inhibitor (ICI) | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Kidney cancer | |
| 650 | 4 | |a Renal cell carcinoma (RCC) | |
| 650 | 7 | |a Antineoplastic Agents, Immunological |2 NLM | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 700 | 1 | |a Battle, Dena |e verfasserin |4 aut | |
| 700 | 1 | |a Figlin, Robert A |e verfasserin |4 aut | |
| 700 | 1 | |a George, Daniel J |e verfasserin |4 aut | |
| 700 | 1 | |a Hammers, Hans |e verfasserin |4 aut | |
| 700 | 1 | |a Hutson, Tom |e verfasserin |4 aut | |
| 700 | 1 | |a Jonasch, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Joseph, Richard W |e verfasserin |4 aut | |
| 700 | 1 | |a McDermott, David F |e verfasserin |4 aut | |
| 700 | 1 | |a Motzer, Robert J |e verfasserin |4 aut | |
| 700 | 1 | |a Pal, Sumanta K |e verfasserin |4 aut | |
| 700 | 1 | |a Pantuck, Allan J |e verfasserin |4 aut | |
| 700 | 1 | |a Quinn, David I |e verfasserin |4 aut | |
| 700 | 1 | |a Seery, Virginia |e verfasserin |4 aut | |
| 700 | 1 | |a Voss, Martin H |e verfasserin |4 aut | |
| 700 | 1 | |a Wood, Christopher G |e verfasserin |4 aut | |
| 700 | 1 | |a Wood, Laura S |e verfasserin |4 aut | |
| 700 | 1 | |a Atkins, Michael B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal for immunotherapy of cancer |d 2013 |g 7(2019), 1 vom: 20. Dez., Seite 354 |w (DE-627)NLM23381065X |x 2051-1426 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2019 |g number:1 |g day:20 |g month:12 |g pages:354 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s40425-019-0813-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2019 |e 1 |b 20 |c 12 |h 354 | ||